2025-524080-20-00RecruitingPhase 1
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 29 Apr 2026
- Start date
- 8 Oct 2026
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Prostate cancer
- EU CT number
- 2025-524080-20-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 26
- 6 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic castration resistant prostate cancer. It studies INR731 alone or with an androgen receptor pathway inhibitor (ARPI).
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration resistant prostate cancer
Read by machine on 9 Nov 2026.
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR | Dresden | Germany | Recruiting |
| Universitaetsklinikum Wuerzburg AöR | Wuerzburg | Germany | Recruiting |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Recruiting |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | Recruiting |
| Institut Bergonie | Bordeaux | France | Not yet recruiting |
| ASST Grande Ospedale Metropolitano Niguarda | Milan | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.